Dr. Daniel A. Solomon, M.D
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 142
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Yale University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MA license 254553 -
Internal Medicine Physician
MA license 244196
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- South Shore Hospital South Weymouth, MA
Medical groups
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 142
- Services billed
- 438
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 119 | 55 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 39 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 69 |
| Doxycycline Monohydrate Other prescribers in Boston, MA | 30 |
| Methenamine Hippurate Other prescribers in Boston, MA | 27 |
| Acyclovir Other prescribers in Boston, MA | 22 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Boston, MA | 18 |
| Suboxone (buprenorphine hcl/naloxone hcl) Other prescribers in Boston, MA | 16 |
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Boston, MA | 16 |
| Amoxicillin Other prescribers in Boston, MA | 15 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 13 |
| Tivicay (dolutegravir sodium) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $13.74 in total to this clinician.
| Ferring Pharmaceuticals Inc. | $13.74 |
|---|
| Food and Beverage | $13.74 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $315,739 in research payments for these studies, mostly to the institutions running them.
- Urate Lowering Treatment and Cardiovascular Risk: A Sub-Study of the TRUST Trial
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.